Cyclosporine before PCI in Patients with Acute Myocardial Infarction - École Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation ENSBANA Access content directly
Journal Articles New England Journal of Medicine Year : 2015

Cyclosporine before PCI in Patients with Acute Myocardial Infarction

Olivier Morel
  • Function : Author
  • PersonId : 757135
  • IdRef : 192420062
David Garcia-Dorado
  • Function : Author
Patrice Guérin
  • Function : Author
Meier Elbaz
  • Function : Author
Nicolas Delarche
  • Function : Author
Marc Metge
  • Function : Author
Jean-François Aupetit
  • Function : Author
Bernard Jouve
  • Function : Author
Pascal Motreff
  • Function : Author
Jean-Noel Labeque
  • Function : Author
Grégoire Range
  • Function : Author
Jérome Clerc
  • Function : Author
Marc J. Claeys
  • Function : Author
Patrick Coussement
  • Function : Author
Frédéric Moulin
  • Function : Author
  • PersonId : 857061
Olivier Roth
  • Function : Author
Philippe Dubois
  • Function : Author
  • PersonId : 1010632
Patrice Colin
  • Function : Author
Fabien de Poli
  • Function : Author
Marie-Claude Morice
  • Function : Author
Omar Ider
  • Function : Author
Thierry Unterseeh
  • Function : Author
Thierry Béard
  • Function : Author
Gilles Grollier
  • Function : Author
Vincent Malquarti
  • Function : Author
Patrick Staat
  • Function : Author
Arnaud Sudre
  • Function : Author
Eskil Elmer
  • Function : Author
Magnus J. Hansson
  • Function : Author
Inesse Boussaha
  • Function : Author
Claire Jossan
  • Function : Author
Michel Ovize
  • Function : Author

Abstract

BACKGROUND: Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce myocardial infarct size. We aimed to test whether cyclosporine would improve clinical outcomes and prevent adverse left ventricular remodeling. METHODS: In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation myocardial infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset and who had complete occlusion of the culprit coronary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization. The primary outcome was a composite of death from any cause, worsening of heart failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ventricular remodeling at 1 year. Adverse left ventricular remodeling was defined as an increase of 15% or more in the left ventricular end-diastolic volume. RESULTS: A total of 395 patients in the cyclosporine group and 396 in the placebo group received the assigned study drug and had data that could be evaluated for the primary outcome at 1 year. The rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds ratio, 1.04; 95% confidence interval [CI], 0.78 to 1.39; P=0.77). Cyclosporine did not reduce the incidence of the separate clinical components of the primary outcome or other events, including recurrent infarction, unstable angina, and stroke. No significant difference in the safety profile was observed between the two treatment groups. CONCLUSIONS: In patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year. (Funded by the French Ministry of Health and NeuroVive Pharmaceutical; CIRCUS ClinicalTrials.gov number, NCT01502774; EudraCT number, 2009-013713-99.)
Fichier principal
Vignette du fichier
nejmoa1505489.pdf (434.43 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-01260566 , version 1 (11-06-2021)

Identifiers

Cite

Thien-Tri Cung, Olivier Morel, Guillaume Cayla, Gilles Rioufol, David Garcia-Dorado, et al.. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. New England Journal of Medicine, 2015, 373 (11), pp.1021--1031. ⟨10.1056/NEJMoa1505489⟩. ⟨hal-01260566⟩
537 View
109 Download

Altmetric

Share

Gmail Facebook X LinkedIn More